bluuebunny/crossref_metadata_2025_split huggingface dataset:
Correlation of Red Blood Cells and Platelets Parameters.
Authors: Saouli Zoi , Kaiafa Georgia , Girtovitis Fotios , Kontoninas Zisis , Ntaios George , Charisopoulos George , Tsavdaridou Vasiliki , Aggouridaki Christina , Papadopoulos Athanasios 
Published: October 2019

Abstract
INTRODUCTION: Platelet along with red blood cell count is a part of complete blood cell count, one of the most frequent laboratory tests in medicine. Platelet distribution width, plateletcrit and mean platelet volume are three indices provided by hematological analyzers. There are few reports in literature regarding the correlation of these three parameters with red blood cell parameters.
AIM: Aim of this study is to investigate the correlation between these platelets parameters and red cell parameters: hematocrit, mean corpuscular volume and red blood cell distribution width.
METHODS: Three hundred and three healthy blood donor volunteers (176 men and 127 women, mean age 37,3 years) were included. None of them had any known hematological disease in the past. The parameters mentioned above were measured by the automated hematological analyzer Coulter®LH780.
RESULTS: The mean values for platelets were: PCT: 0,25±0,11%, MPV: 8,11±1,94 fL and PDW: 15,89±2,74%. The mean values for their parallel red blood cell parameters were: HCT: 40,55±2,63%), MCV: 91±4,17 fL, RDW: 13,3±1,35% Statistical and regression analysis including the correlation coefficient between platelet and red cell parameters as well as Student’s t-test was carried out.
CONCLUSIONS:
There seems to be no significant correlation between HCT and PCT. MCV and MPV were not correlated significantly as well, indicating that red blood cell and platelet sizes are independent. But there is a statistically significant correlation between RDW and PDW (r: 0,68, p<0,01) demostrating that anisocytosis of red blood cells and platelets might occur simultaneously. Based on these observations, further more studies should be carried out for the correlation between platelets and red blood cell indices in certain disorders.
Rabbit Antithymocyte Globulin in Treatment of Children with Severe Aplastic Anemia.
Authors: Pawelec Katarzyna , Matysiak Michal J. , Niewiadomska Edyta , Jerzy Kowalczyk , Stefaniak Jolanta , Balwierz Walentyna , Zaleska-Czepko Ewa , Chybicka Alicja , Szmyd Krzysztof , Sonta-Jakimczyk Danuta , Bubala Halina , Wysocki Mariusz , Kurylak Andrzej , Wachowiak Jacek , Kaczmarek-Karnold Malgorzata , Stolarska Malgorzata , Krawczuk-Rybak Maryna , Leszczynska Elzbieta , Urasinski Tomasz , Peregud-Pogorzelski Jaroslaw , Balcerska Anna , Wlazlowski Marek 
Published: October 2019

Abstract
In children with severe aplastic anemia (SAA) bone marrow transplantation is the chosen therapy. However, it is only possible in about 15–20% patients who have family donors. Immunosuppressive therapy (IST) is administered in the remaining cases. 105 children in 11 hematology centers of the Polish Pediatric Hematology Group (PPHG) were given IST treatment. 27 patients (12 girls and 15 boys aged 6–16 years) received antithymocyte rabbit globulin (ATG) in the first course of therapy. ATG was administered according to PPHG and Working Party SAA Group of EBMT protocol: ATG 3.75mg/kg iv for 5 days, cyclosporin A (CSA) 5mg/kg orally from day 1 to day 180 and granulocyte-stimulating factor during deep neutropenia. Remission of the disease was assessed on days 84, 112 and 180 from start of therapy on the basis of blood and bone marrow examination. On day 180 remission was obtained in 17 of 27 patients (62.9%), complete remission (CR) in 11 children (40.7%) and partial remission in 6 children (22.2%) There was no response to treatment (NR) in 10 patients (37%). In the no response group, 1 child died and 4 had bone marrow transplants from unrelated donors. The remaining 5 patients received a second course of IST therapy, and 2 of them had CR. In the group of 27 patients, 4 died (14.8%). 2 of them died early (day 52 and day 72 of therapy) due to septicemia and central nervous system (CNS) hemorrhage. The other 2 died late (day 99 and day 365of therapy) due to CNS hemorrhage. Observation time of patients ranged from 1 to 13 years. During this time we noted one relapse. MDS/AML or PNH was not observed in any of the patients. The probability of 13 year survival is 85.1% in our group. Our data suggest that initial SAA treatment with ATG is safe and effective in children. Further studies are needed, however, to assess long-term effectiveness of ATG in IST.
Results of Immunosuppressive Therapy in Children with Severe Aplastic Anaemia (SAA). Report Polish Pediatric Hematology Group (Warszawa, Lublin, Krakow, Wroclaw, Zabrze, Bydgoszcz, Poznan, Lodz, Bialystok, Szczecin, Gdansk).
Authors: Pawelec Katarzyna , Matysiak Michal , Niewiadomska Edyta , Kowalczyk Jerzy , Stefaniak Jolanta , Balwierz Walentyna , Zaleska-Czepko Ewa , Chybicka Alicja , Szmyd Krzysztof , Sonta-Jakimczyk Danuta , Bubala Halina , Wysocki Mariusz , Kurylak Andrzej , Wachowiak Jacek , Kaczmarek-Karnold Malgorzata , Stolarska Malgorzata , Krawczuk-Rybak Maryna , Leszczynska Elzbieta , Urasinski Tomasz , Peregud-Pogorzelski Jaroslaw , Balcerska Anna , Wlazlowski Marek 
Published: October 2019

Abstract
Introduction: Bone marrow transplantation (BMT) from HLA identical family donors is the treatment chosen, according indication of Polish Pediatric Hematology Group, for children with severe aplastic anemia (SAA). When no donor is available, combined immunosuppressive therapy (IST) is given.
Material and method: SAA was recognized in 105 children (42 girls, 73 boys) aged 2–18 years in eleven pediatric hematological center in Poland between 1993–2006 years. All patients received IST according Polish Pediatric Hematology and Working Party SAA of the EBMT protocol: antithymocyte globulin horse or rabbit, cyclosporine A (CSA), prenisolon and in 79 patients G-CSF or GM-CSF was additionally administered. Hematological response was evaluated on day 84 and 180 of therapy.
Results and conclusion: On day 180 remission was obtained in 80 from 105 patients (76.1%), complete remission (CR) in 53 patients (51.5%), partial remission (PR) in 27 (24.7%), There was no response to treatment (NR) in 25 patients (23.8%). Period of observation was from 10 months to 13 years. During this time relapse occurred in 28 patients (25.7%). Patients with NR and relapse were treated second course of IST or BMT from matched bone marrow donors. Unrelated BMT was performed in 15 patients with NR after IST. We observed 22 deaths (8 early during the first 3 months of IST) in all group. During the 13 year of observation we notice one case with late clonally complication (PNH), one case of transformation to AML and one to MDS. Probably of 13 year survival was 75.2% in our group. Our results are effective and compared to other hematological centers.
CD4+CD25+ Regulatory T Cells in Patients with Acute Lymphocytic Leukemia.
Authors: Cao Xiangshan , Xie Xiaobao , Li Aaihua , Qiu Guoqiang 
Published: October 2019

Abstract
Human CD4+CD25+ regulatory T (Treg) cells suppress antigen-specific T cell immune response and contribute to peripheral tolerance. However, little is known about the role of Treg cells in the pathogenesis of acute lymphocytic leukemia (ALL). In this study, the proportion of CD4+CD25+ Treg cells in the peripheral blood of three groups of people [the patients with ALL who had never received any chemotherapy before, the patients with ALL who had achieved partial remission (PR) or complete remission (CR) after chemotherapy and the healthy donors] was evaluated by flow cytometry. The expression level of Foxp3 mRNA of each group was examined by real-time RT-PCR. In vitro, the peripheral blood mononuclear cells (PBMC) from healthy donors were cultured in the serum of ALL patients without chemotherapy; each group was divided into sub-groups according to various serum doses. After co-cultured for 72 hours, the cells of all the groups were harvested separately and further tested the number of CD4+CD25+ Treg cells and the mRNA expression of Foxp3. The results showed that both the percentage of CD4+CD25+ T cells and the mRNA expression level of Foxp3 in patients with chemotherapy were significantly higher than those of the healthy donors and patients without chemotherapy (P<0.01 and P<0.01). Although the population of CD4+CD25+ T cells in ALL patients without chemotherapy was almost the same to that in the healthy donors (P>0.05), the expression of Foxp3 mRNA in former was higher (P<0.05) .The serum derived from ALL patients without chemotherapy remarkably increased the proportion of CD4+CD25+ T cells and the expression level of Foxp3 mRNA in co-cultured system, both of which were statistically higher than those in controls (P<0.05 and P<0.01) and did not vary with the serum dose. These results suggest that the chemotherapy may exert an influence on the production of CD4+CD25+ Treg cells and CD4+CD25+ Treg cells may play an important role in the pathogenesis of ALL.
Platelet Counts Remain Elevated in Two Patients with Idiopathic Thrombocytopenic Purpura after Cessation of Oral Eltrombopag.
Authors: Cheng Gregory 
Published: October 2019

Abstract
Idiopathic thrombocytopenic purpura (ITP) is a disease of inadequate platelet production and increased platelet destruction. Two randomized, double-blind, placebo-controlled trials (TRA100773 A/B) reported that eltrombopag, the first-in-class, oral, platelet growth factor, results in a dose-dependent increase in platelet counts in adult patients with chronic ITP. After treatment of eltrombopag was stopped, platelet counts returned to baseline levels in most patients within 2 weeks, reflecting the normal platelet lifespan (range, 10–14 days). This abstract presents data on two patients enrolled in TRA100773 A/B in whom a prolonged platelet count elevation was observed after cessation of eltrombopag treatment. A 79-year old Asian female (Patient 1) was diagnosed with ITP in September 2003. Prior ITP therapy included prednisolone and Danazol simultaneously in 1997. Prednisolone was stopped after 10 months. Danazol was continued until March 2005 (Day -50). The patient relapsed in March 2005 and received dexamethasone (5 days), IVIg (once), vincristine, and cyclosporin A without a significant response. Eltrombopag treatment was started in May 2005 leading to an increase in platelet counts that remained elevated above 100,000/uL after treatment with eltrombopag was discontinued (Table). Patient 2, a 49-year old Asian female, was diagnosed with ITP in 1997. She relapsed after two courses of dexmethasone 40 mg, QD × 4, administered in September 2003 with a 3-month response and in January 2006 with a 1-month response. Therapy with eltrombopag was initiated in March 2006. As was seen with Patient 1, platelet counts increased after administration of eltrombopag and remained elevated after cessation of eltrombopag (Table). To the best of our knowledge, this is the first report of an ongoing prolonged elevation of platelet counts after cessation of thrombopoietic medication, such as eltrombopag.
Platelet Counts (/uL) Patient 1 Patient 2 *Eltrombpag withdrawn in both patients. Screening 26,000 69,000 Day 1 26,000 26,000 Day 8 193,000 136,000 Day 15* 591,000 283,000 Day 22 664,000 --- Day 50 --- 260,000 Day 57 330,000 116,000 Day 71 112,000 100,000 Day 85 116,000 111,000
Haemostatic Actions of the Folkloric Medicinal Plant Extract, Ankaferd Blood Stopper.
Authors: Goker Hakan , Haznedaroglu Ibrahim C. , Ercetin Sevil , Kirazli Serafettin , Akman Umit , Ozturk Yusuf , Firat Cahit H. 
Published: October 2019

Abstract
Ankaferd Blood Stopper® (ABS), a standardized mixture of the plants Thymus vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum, and Urtica dioica has been used as a haemostatic agent. However, the essential ‘mechanism of action’ of ABS is currently unknown. The aim of this study is to search the essential mechanism underlying the haemostatic actions of ABS. In our study, ABS induced a very rapid (less than 1 second) formation of a protein network within the plasma and serum. Individual clotting factors namely factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XIII are not affected during the consecutive measurements. Plasma fibrinogen activity and antigen decreased from 302 mg/dl to 10 mg/dl, and fibrinogen antigen decreased from 299 mg/dl to 30 mg/dl, in parallel to the prolongation of thrombin time (TT). Biochemical tests also revealed that total protein, albumin, and globulin levels significantly decreased with the interactions of ABS. Red blood cells come together to form vital erythrocyte mass blocks in the presence of ABS. Vital physiological red blood cell aggregation after the exposure to Ankaferd Bloood Stopper in less than one second is depicted in Figure 1. The network of ABS could cover the entire physiological haemostatic process without unequally disturbing individual clotting factors. The basic mechanism of action for ABS appears to be the formation of an encapsulated protein network representing focal points as a niche for vital erythrocyte aggregation. ABS is a novel effective haemostatic agent that has the therapeutic potential for the management of hemorrhage in medical practice. Clinical trials with that promising medicine can provide the development of a new drug particularly active in pathological haemostasis.
Figure Figure
A Pharmacokinetic Study of the Plasma-Derived Factor IX AlphaNine® and Its Comparison with the Recombinant Factor IX BeneFIX®, in Previously Treated Patients with Severe Hereditary Hemophilia B.
Authors: Cortina Vicente R. , Lissichkov T. , Zavilska K. , Matysiak M. , Gercheva L. , Aznar José A. 
Published: October 2019

Abstract
Objectives The objective of the present study was two fold: first, to determine the pharmacokinetic (PK) profile of the plasma-derived FIX concentrate AlphaNine® in patients with congenital severe haemophilia B (FIX:C 2%). To do this, two PK studies were carried out one six months after the first. The second objective was a comparison of the Alphanine® PK profile with the recombinant Factor IX, BeneFIX®.
Patients and methods The first study was a prospective, five-center, open-label, comparative, PK study carried out in 25 severe hemophilia B patients who received 2 single doses of 65–75 IU/kg of AlphaNine® within 6 months (t=0 and t=6). The following parameters were assessed: in vivo recovery, half-life, AUC, mean residence time and clearance. As an extension of the study, a single dose of 65–75 IU/kg of BeneFIX® was administered in 9 out of 25 patients, after a wash-out period of 7–15 days.
Results Table 1 summarizes the results obtained when comparing AlphaNine® within a period of time of 6 months (PK1 vs PK2) in 25 patients. Table 2 shows the results obtained when comparing the in vivo recovery of AlphaNine ® vs BeneFIX ® in the 9 patients studied.
Conclusions These results confirm that AlphaNine® PK has similar profile as other plasma derived FIX products presently available to treat Hemophilia B patients. In addition, our results show that the recombinant FIX studied, BeneFIX® has a reduced in vivo recovery when is compared to AlphaNine®.
Table 1 Parameter AlphaNine® (PK1) t=0 m AlphaNine® (PK2) t=6 m Results are expressed as Mean (SD) In vivo recovery (IU/dl:IU/kg) 1.0 (0.2) 1.2 (0.4) Half-life (h) 34.5 (6.2) 33.7 (5.4) Clearance (ml/min) 0.07 (0.01) 0.07 (0.01) AUC0-inf (IUxh/dl) 1602 (312) 1644 (360) MRT0-inf (h) 35.8 (5.4) 34.6 (5.2) Table 2 Parameter AlphaNine® (PK2) BeneFIX® Results are expressed as Mean (SD); * p<0.05 for the comparison of the in vivo recovery for the BeneFIX® group with the AlphaNine® PK2 In vivo recovery (IU/dl:IU/kg) 1.3 (0.5) 0.8 (0.2)*
Antiphospholipid Antibody Syndrome: The Flow Cytometric Annexin A5 Competition Assay as a Diagnostic Tool.
Authors: Tomer Aaron , Bar-Lev Shira , Fleisher Stela , Shenkman Boris , Friger Michael , Abu-Shakra Mahmoud 
Published: October 2019

Abstract
The mechanism underlying hypercoagulability in antiphospholipid antibody syndrome (APS) is uncertain. Here, we present a flow-cytometric assay (FCA) based on the hypothesis that anti-platelet-anionic-phospholipid autoantibodies (aPL) interfere with the activity of the natural anticoagulant protein annexin A5, thereby accelerating platelet procoagulant activity. This study assessed the clinical utility of the feasible FCA, which demonstrates the competition of the patient’s aPL with the binding of annexin A5 to the platelet-anionic-phospholipids, in the diagnosis of APS. Sixty-two (94%) of 66 APS patients, 20 (51%) of 39 patients with systemic lupus erythematosus and two (4%) of 49 healthy individuals were positive by FCA. Compared with the anticardiolipin (aCL) assay, the relative sensitivity was 82% and the specificity 73∴3%. However, 19 (25%) aCL-negative patients were positive by FCA; 12 were positive for lupus-anticoagulant (LA). Compared with LA assay, the relative sensitivity was 85% and the specificity 72∴2%. However, 21 (26%) LA-negative patients were FCA-positive, 12 were positive for aCL. The FCA was particularly sensitive for APS patients with arterial (97∴0%) and gestational vascular complications (100%) with overall sensitivity of 95% and specificity of 97%. Our findings suggest that the FCA is practical, sensitive and specific for the detection of clinically relevant aPL in the diagnosis of APS.
Differential Procoagulant Phenotype of Pancreatic and Breast Cancer Cells Related to Different Tissue Factor Activity.
Authors: Gerotziafas Grigoris T. , Elalamy Ismail , Roman Marie-Paule , Prengel Claudine , Verdy Elisabeth , Bernaudin Jean-François 
Published: October 2019

Abstract
Tissue factor (TF) expressed by some cancer cells is implicated in metastasis and angiogenesis. The influence of cancer cells on blood coagulation has not been adequately studied. We evaluated the procoagulant potential of pancreatic and breast cancer cells (BXPC3 and MCF7 cell lines respectively) when they are in contact with human platelet-poor plasma (PPP). At 40% and 90% confluence, adhesive cultures of BXPC3 and MCF7 cells were treated with trypsine according to standardized procedure and cancer cells were suspended in normal human platelet poor plasma (PPP) at increasing concentrations. Coagulation was triggered by CaCl2 addition and thrombin generation (TG) was monitored using the Calibrated Automated Thrombogram-Thrombinoscope® (Biodis-France). In some experiments, cancer cells were incubated for 30 min with a polyclonal specific anti-TF antibody (American Diagnostics). Cancer cells accelerated TG by decreasing significantly lag-time, and time to Peak of thrombin (ttPeak) but they did not significantly influence the endogenous thrombin potential. BXPC3 had significantly more potent procoagulant activity compared to MCF7 cells. Incubation of cancer cells with anti-TF antibody resulted in a concentration dependent inhibition of their procoagulant effect. The IC50 of the anti-TF antibody for TG induced by BXPC3 was about 10-fold higher to that for MCF7. Pancreatic cancer cells (BXPC3) and breast cancer cells (MCF7) accelerate thrombin generation of human plasma in a TF-dependent manner. BXPC3 have more potent procoagulant activity than MCF7 probably due to increased TF expression.
Combined Antithrombotic Therapy but Not Single-Agent Therapy with Low-Dose Aspirin Deteriorated Platelet Activation in Patients with Antiphospholipid Syndrome (APS).
Authors: Yamazaki Masahide , Kadohira Yasuko , Morishita Eriko , Asakura Hidesaku , Nakao Shinji 
Published: October 2019

Abstract
Antiphospholipid syndrome (APS) is one of autoimmune disorders characterized with recurrent thromboses. It is considered that plasma levels of D-dimer and prothrombin fragment 1+2 (F1+2) could reflect hypercoagulable state in APS patients and those monitoring may be useful for a predictor of venous thromboses. In contrast, the estimation of platelet activation is difficult. Recently, plasma levels of platelet-derived microparticle (PDMP), which released from activated platelets, could be measured using ELISA supplied from JIMRO Co. JAPN (“JIMRO test PDMP”). We previously presented that plasma levels of PDMP were significantly elevated in APS-patients with arterial thromboses and that could reflect platelet activated condition in vivo. To evaluate the preventory effect of thromboses and the inhibitory effects for platelet activation by several kinds of antithrombotic agents in APS, 30 APS patients with cerebral infarctions were randomly treated with low-dose aspirin alone (Group A, n=10), aspirin plus warfarin (Group B, n=10), or aspirin plus cirostazole (Group C, n=10). Their plasma PDMP levels were measured using “JIMRO test PDMP” (JIMRO Co., JAPAN) before and after antithromboitic treatment on a regular schedule, and MRI brain scans were also underwent in every six months. Plasma PDMP levels in group B and group C significantly decreased by combined antithrombotic therapy (18.0 ± 7.1 to 13.0 ± 8.2 U/mL, 17.8 ± 6.7 to 12.4 ± 7.8 U/mL, p &lt; 0.03 and &lt; 0.01, respectively) but not in Group A (18.2 ± 8.1 to 17.9 ± 9.1, NS). Brain MRI revealed worsening of lacuna infarctions in only one patient in Group A. No serious adverse effects were shown in any patients. These findings suggest that single use of aspirin could be enough for prevention of arterial thrombosis in APS patients and that plasma PDMP levels may be useful for an indicator of antiplatelet therapy.
Gestational Age Above 12 Weeks Predicts Favorable Obstetric Outcome in Women with Antiphospholipid Syndrome (APS) Associated with First-Trimester Recurrent Pregnancy Loss (RPL) Treated with Enoxaparin and Low Dose Aspirin.
Authors: Noble Luis S. , Herrada Juan , Kutteh William H. 
Published: October 2019

Abstract
Background: Pregnant women with APS associated with RPL treated with enoxaparin and low dose aspirin (ASA) resulted in an 84% viable infant delivery (Fertil Steril. 2005 Mar;83(3):684–90).
Design and Methods: Retrospective analysis. 30 patients (pts) were enrolled. Mean chronological age was 33.4 years. All pts had 2 or more first trimester losses and had a complete evaluation for RPL including anatomical, hormonal, infectious, chromosomal, and immunological. A standard ELISA was employed to detect the presence of IgG, IgM, and IgA serum antibodies against the phospholipids cardiolipin, inositol, serine, and ethanolamine. All pts received ASA 81 mg orally and enoxaparin 40 mg subcutaneously daily as soon as the serum pregnancy test became positive. Pts were monitored at monthly intervals.
Results:

Conclusions: We did not observe miscarriages in pregnant women with APS associated with first trimester RPL treated with enoxaparin and low dose aspirin after the 12th week of pregnancy.